#AAIC21 – Phase 3 Trial of Anti-inflammatory NE3107 Begins Enrolling

#AAIC21 – Phase 3 Trial of Anti-inflammatory NE3107 Begins Enrolling

302621

#AAIC21 – Phase 3 Trial of Anti-inflammatory NE3107 Begins Enrolling

A Phase 3 trial testing NE3107, BioVie’s experimental anti-inflammatory insulin-sensitizing therapy, in adults with mild to moderate Alzheimer’s disease has enrolled its first patient. The study, called NM101 (NCT04669028), seeks to enroll up to 316 patients, ages 55–85 years at two sites in Florida. “NE3107 is the first potentially disease modifying, anti-inflammatory insulin sensitizer therapy in a phase 3 trial” of people with mild to moderate Alzheimer’s, Cuong Do, BioVie’s president and CEO, said in…

You must be logged in to read/download the full post.